Literature DB >> 28656027

Combination Therapy for Inflammatory Bowel Disease.

Stephen B Hanauer1.   

Abstract

Year:  2017        PMID： 28656027      PMCID： PMC5479343     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.

Authors:  J-F Colombel; W Reinisch; G J Mantzaris; A Kornbluth; P Rutgeerts; K L Tang; A Oortwijn; G S Bevelander; F J Cornillie; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2015-03-01       Impact factor: 8.171

Review 2.  Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.

Authors:  Parambir S Dulai; Corey A Siegel; Jean-Frederic Colombel; William J Sandborn; Laurent Peyrin-Biroulet
Journal:  Gut       Date:  2014-06-26       Impact factor: 23.059

Review 3.  Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.

Authors:  Jennifer L Jones; Gilaad G Kaplan; Laurent Peyrin-Biroulet; Leonard Baidoo; Shane Devlin; Gil Y Melmed; Divine Tanyingoh; Laura Raffals; Peter Irving; Patricia Kozuch; Miles Sparrow; Fernando Velayos; Brian Bressler; Adam Cheifetz; Jean-Frederic Colombel; Corey A Siegel
Journal:  Clin Gastroenterol Hepatol       Date:  2015-06-30       Impact factor: 11.382

4.  Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.

Authors:  J-F Colombel; B Jharap; W J Sandborn; B Feagan; L Peyrin-Biroulet; S F Eichner; A M Robinson; N M Mostafa; Q Zhou; R B Thakkar
Journal:  Aliment Pharmacol Ther       Date:  2016-11-07       Impact factor: 8.171

Review 5.  Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.

Authors:  Joana Torres; Ray K Boyapati; Nicholas A Kennedy; Edouard Louis; Jean-Frédéric Colombel; Jack Satsangi
Journal:  Gastroenterology       Date:  2015-09-14       Impact factor: 22.682
  5 in total
  3 in total

1.  Improving IBD Care: A Personalized Approach to Management.

Authors:  Stephen B Hanauer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

2.  Apoptosis markers of circulating leukocytes are associated with the clinical course of inflammatory bowel disease.

Authors:  Azade Amini Kadijani; Fariba Javadinia; Alireza Mirzaei; Zeinab Khazaei Koohpar; Hedieh Balaii; Shaghayegh Baradaran Ghavami; Zahra Gholamrezaei; Hamid Asadzadeh-Aghdaei
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018

3.  Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Paul B Larkin; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2021-11-15       Impact factor: 5.325
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.